The HTX-011 Story
HTX-011 Breakthrough in Pain Management ZYNRELEF, the commercial name for HTX-011, is the first and only FDA-approved extended-release dual-acting...
HTX-011 Breakthrough in Pain Management ZYNRELEF, the commercial name for HTX-011, is the first and only FDA-approved extended-release dual-acting...
It is important to bridge the gap between lab findings and clinical applications using translational models, ensuring effective translation for human...
Understanding Mechanisms Underlying Neuropathic Pain
Advancing Beyond Rodent and Non-Human Primate Models While rodent models have contributed significantly to our understanding of various diseases and...
The goal of preclinical drug development is to identify potential therapeutic compounds and gain an understanding of disease pathways or target...
Neuroma in humans is a challenging condition that often leads to persistent pain in residual limbs. Despite its prevalence, this condition proves to...
MD Biosciences has published a new article in the Journal of Pain describing a novel sensory wave (P25) in the MOG-induced EAE model. This article...
As the general population continues to age, the economic burden of chronic pain and neurodegenerative diseases is increasing and becoming...
An excerpt from MD Biosciences publication in the Autumn 2022 issue of Göttingen Minipigs Magazine. MD Biosciences operates a neuroscience research...